TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Beijing Tong Ren Tang Chinese Medicine Co ( (HK:3613) ) has shared an update.
Beijing Tong Ren Tang Chinese Medicine Co has announced the termination of its Current Trademark Licence Agreement with Tong Ren Tang Holdings, effective from December 31, 2025. A new agreement, the New Trademark Licence Framework Agreement, has been signed, allowing the company to use the ‘Tong Ren Tang’ tradename and certain trademarks from January 1, 2026, to December 31, 2027. This agreement is categorized as a continuing connected transaction under Hong Kong’s Listing Rules, requiring reporting and annual review but exempt from independent shareholder approval. The new licensing terms include a fee structure based on the company’s operating revenue, potentially impacting its financial obligations and market operations.
The most recent analyst rating on (HK:3613) stock is a Hold with a HK$9.50 price target. To see the full list of analyst forecasts on Beijing Tong Ren Tang Chinese Medicine Co stock, see the HK:3613 Stock Forecast page.
More about Beijing Tong Ren Tang Chinese Medicine Co
Beijing Tong Ren Tang Chinese Medicine Co is a company incorporated in Hong Kong, primarily engaged in the Chinese medicine industry. The company focuses on the production and distribution of traditional Chinese medicine products, leveraging the well-established ‘Tong Ren Tang’ brand.
Average Trading Volume: 1,193,291
Technical Sentiment Signal: Hold
Current Market Cap: HK$7.46B
For an in-depth examination of 3613 stock, go to TipRanks’ Overview page.